Document Detail

Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.
MedLine Citation:
PMID:  16867902     Owner:  NLM     Status:  MEDLINE    
This retrospective study investigated the effects of rituximab in 19 pediatric patients (15 girls and 4 boys) with chronic refractory symptomatic immune thrombocytopenic purpura (ITP). Patients received from 2 to 5 weekly infusions of rituximab (375 mg/m(2)); 15 patients were younger than 12 years when treated. The median follow-up time was 30 months (range, 9-43 months). The overall response rate was 68% (13/19 patients). Six responders relapsed at a median of 4.5 months (range, 3-8 months). Seven patients still displayed a platelet count >150,000/microL at a median of 33 months (range, 14-43 months) after rituximab treatment. Six of 15 patients treated with 4 or 5 weekly infusions and 1 of 4 patients treated with 2 or 3 infusions are still in remission. No difference was detected between splenectomized and nonsplenectomized patients. The duration of ITP disease at the time of treatment did not influence the response rate. Patients still in remission showed significantly lower levels of CD19+ cells after 4 and 6 months than nonresponding or relapsed patients (P < .05). No major infections were reported during follow-up. Our data show the efficacy and tolerability of rituximab in young children with refractory symptomatic ITP. Nonrelapsed patients showed a more prolonged B-cell depletion.
Emilia Parodi; Bruno Nobili; Silverio Perrotta; Sofia Maria Rosaria Matarese; Giovanna Russo; Maria Licciardello; Marco Zecca; Franco Locatelli; Simone Cesaro; Gianni Bisogno; Paola Giordano; Domenico De Mattia; Ugo Ramenghia
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of hematology     Volume:  84     ISSN:  0925-5710     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-07-26     Completed Date:  2006-09-15     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  48-53     Citation Subset:  IM    
Pediatric Department, University of Torino, Torino, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage*
Antigens, CD19
Blood Transfusion
Child, Preschool
Chronic Disease
Clinical Trials as Topic
Follow-Up Studies
Immunologic Factors / administration & dosage*
Purpura, Thrombocytopenic, Idiopathic / blood,  therapy*
Remission Induction
Retrospective Studies
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD19; 0/Immunologic Factors; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Collection by a simple bag method and the function of granulocytes in granulocyte transfusion.
Next Document:  Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3.